Glen A. Taylor - 12 Feb 2026 Form 4 Insider Report for Envoy Medical, Inc. (COCH)

Role
10%+ Owner
Signature
/s/ Glen A. Taylor
Issuer symbol
COCH
Transactions as of
12 Feb 2026
Net transactions value
+$7,500,000
Form type
4
Filing time
17 Feb 2026, 13:35:17 UTC
Previous filing
08 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
TAYLOR GLEN A 10%+ Owner C/O TAYLOR CORP, 1725 ROE CREST DR, N MANKALO /s/ Glen A. Taylor 16 Feb 2026 0001213971

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction COCH Class A Common Stock Purchase $7,500,000 +18,750,000 +635% $0.4000 21,703,607 12 Feb 2026 Direct
holding COCH Class A Common Stock 2,526,058 12 Feb 2026 By Taylor Sports Group F1
holding COCH Class A Common Stock 4,810,384 12 Feb 2026 By GAT Funding, LLC F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction COCH Warrant Shares (Series A-1) Purchase $0 +11,250,000 $0.000000 11,250,000 12 Feb 2026 Class A Common Stock 11,250,000 $0.4000 Direct F3, F4
transaction COCH Warrant Shares (Series A-2) Purchase $0 +18,750,000 $0.000000 18,750,000 12 Feb 2026 Class A Common Stock 18,750,000 $0.4000 Direct F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person is the owner and chairman of Taylor Sports Group.
F2 GAT Funding, LLC is an entity controlled by Reporting Person.
F3 The Series A-1 Warrants and Series A-2 Warrants (the "Common Warrants") will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Common Warrants (the "Stockholder Approval Date").
F4 The Series A-1 Warrants expire on the earlier of (i) the twenty-four month anniversary of the Stockholder Approval Date and (ii) thirty days following the date the Company publicly announces that it has submitted a Premarket Approval Application (PMA) to the U.S. Food and Drug Administration for its Acclaim cochlear implant (the "Series A-1 Milestone Event").
F5 The Series A-2 Warrants expire on the earlier of (i) the sixty-month anniversary of the Stockholder Approval Date and (ii) thirty days following the date the Company publicly announces that it has received U.S. Food and Drug Administration approval for its Acclaim cochlear implant (the "Series A-2 Milestone Event").